SCHEMBL3368246

SCHEMBL3368246

COc1cc(OC)cc(C(=N)N)c1

nearest known ligand 0.64

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
PRSS1 P07477 6/20 0.64
PRSS2 P07478 5/20 0.64
PRSS3 P35030 5/20 0.64
ALDH1A1 P00352 1/20 0.52
PLAU P00749 2/20 0.50
PLG P00747 1/20 0.50
C1S P09871 1/20 0.50
PTGIR P43119 1/20 0.50
ST14 Q9Y5Y6 4/20 0.48
NQO2 P16083 1/20 0.46
F2 P00734 5/20 0.44
F10 P00742 2/20 0.44
PDE4A P27815 2/20 0.44
PDE4B Q07343 2/20 0.44
PDE4C Q08493 2/20 0.44
PDE4D Q08499 2/20 0.44
FURIN P09958 1/20 0.44
PARP1 P09874 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL1436342 0.98 PRSS1 (0.62) PRSS1PRSS2PRSS3ALDH1A1PLAU
SCHEMBL428920 0.79 PRSS1 (1.00) PRSS1PRSS2PRSS3PLGC1S
Hydrochloric Acid SCHEMBL427173 0.77 PRSS1 (0.96) PRSS1PRSS2PRSS3F2F10
Hydrochloric Acid SCHEMBL28548914 0.77 PRSS1 (0.96) PRSS1PRSS2PRSS3F2F10
Hydrochloric Acid SCHEMBL23541004 0.77 PRSS1 (0.96) PRSS1PRSS2PRSS3F2F10
SCHEMBL3373995 0.76 ALDH1A1 (0.52) PRSS1PRSS2PRSS3ALDH1A1PDE4A
SCHEMBL428892 0.76 PRSS1 (1.00) PRSS1PRSS2PRSS3PLAUPTGIR
SCHEMBL894796 0.76 PARP1 (0.64) PRSS1PRSS2PRSS3ALDH1A1PLAU
SCHEMBL23566312 0.74 F2 (0.70) PRSS1PRSS2PRSS3ST14F2
Hydrochloric Acid SCHEMBL5702966 0.74 PRSS1 (0.44) PRSS1PRSS2PRSS3ALDH1A1PLAU

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1476435-B1 NOVEL PYRIDIN- AND PYRIMIDIN-DERIVATIVES HOFFMANN LA ROCHE (CH) 2010-06-30 EP disclosed
CN-1713907-B N-substituted pyrrolidine derivatives as dipeptidyl peptidase IV inhibitors HOFFMANN LA ROCHE 2010-05-26 CN disclosed
CN-1324015-C Pyridine and pyrimidine derivatives HOFFMANN LA ROCHE (CH) 2007-07-04 CN disclosed
US-7022718-B2 Pyridine and pyrimidine derivatives HOFFMANN-LA ROCHE INC. (US) 2006-04-04 US disclosed
CN-1713907-A N-substituted pyrrolidine derivatives as dipeptidyl peptidase IV inhibitors HOFFMANN LA ROCHE (CH) 2005-12-28 CN disclosed
US-20050143405-A1 Pyridine and pyrimidine derivatives BOEHRINGER MARKUS (CH) 2005-06-30 US disclosed
CN-1630644-A Novel pyridine and pyrimidine derivatives HOFFMANN LA ROCHE (CH) 2005-06-22 CN disclosed
US-6867205-B2 Pyridine and pyrimidine derivatives HOFFMAN-LA ROCHE INC. (US) 2005-03-15 US disclosed
EP-1476435-A1 NOVEL PYRIDIN- AND PYRIMIDIN-DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2004-11-17 EP disclosed
WO-2003068757-A9 NOVEL PYRIDIN- AND PYRIMIDIN-DERIVATIVES HOFFMANN LA ROCHE (CH) 2004-10-07 WO disclosed
US-20030216382-A1 Pyridine and pyrimidine derivatives HOFFMAN-LA ROCHE INC. 2003-11-20 US disclosed
WO-2003068757-A1 NOVEL PYRIDIN- AND PYRIMIDIN-DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2003-08-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030216382-A1 Pyridine and pyrimidine derivatives DPP4, GPR119, G6PC1 PRSS1 283/4885PRSS2 1024/4885PRSS3 555/4885
US-20050143405-A1 Pyridine and pyrimidine derivatives DPP4, GPR119, PDXK PRSS1 217/4885PRSS2 895/4885PRSS3 372/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.